Related Experiment Video
Updated: Jul 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Clinical studies: evidence for intervention with specific antiplatelet drugs in arterial thromboembolism
1McMaster University Department of Medicine, Hamilton General Hospital, Ontario, Canada.
Insights
Aspirin effectively treats unstable angina and reduces recurrent TIAs, stroke, and death. Its benefit after myocardial infarction or coronary bypass surgery requires further investigation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Aspirin is widely studied for its antiplatelet effects.
- Its efficacy varies across different cardiovascular conditions.
Purpose of the Study:
- To synthesize evidence on aspirin's effectiveness in various cardiovascular conditions.
- To clarify its role in unstable angina, myocardial infarction, and post-coronary artery bypass surgery.
Main Methods:
- Review of existing clinical evidence and studies.
- Analysis of data regarding aspirin's impact on patient outcomes.
Main Results:
- Conclusive evidence supports aspirin for unstable angina.
- Preoperative dipyridamole with postoperative aspirin is beneficial after coronary artery bypass.
- Evidence for aspirin post-myocardial infarction or alone after bypass is inconclusive.
- Convincing evidence shows aspirin reduces recurrent TIA, stroke, and death.
Conclusions:
- Aspirin is a key treatment for unstable angina and TIA.
- Its role in post-MI and post-CABG settings needs further research.
- The combination of dipyridamole and aspirin shows promise after CABG.
Abstract:
There is conclusive evidence that aspirin is beneficial in patients with unstable angina and that a combination of preoperative dipyridamole with post-operative aspirin is beneficial after coronary artery bypass. The evidence for a beneficial effect of aspirin after myocardial infarction is consistent but inconclusive. The evidence for the use of aspirin alone following coronary bypass is inconclusive. There is convincing evidence that aspirin will reduce the rate of recurrent TIA, stroke, and death in patients with TIA.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

